Liabooks Home|PRISM News

#OpenAI

Total 207 articles

OpenAI's Silent GPT-5.2 Update Is The Loudest Signal Yet About AI's New Reality
TechEN
OpenAI's Silent GPT-5.2 Update Is The Loudest Signal Yet About AI's New Reality

OpenAI's quiet GPT-5.2 update is a strategic signal. Our analysis reveals why this shift from hype to stability marks a new, more mature era for the AI industry.

OpenAI's GPT-5.2 Just Turned AI into a Scientist. This Changes Everything.
TechEN
OpenAI's GPT-5.2 Just Turned AI into a Scientist. This Changes Everything.

OpenAI's GPT-5.2 isn't just another upgrade. Its mastery of math and science signals a fundamental shift from creative AI to a new era of automated discovery.

BNY's 20,000-Strong AI Army: A New Blueprint for Corporate Dominance
TechEN
BNY's 20,000-Strong AI Army: A New Blueprint for Corporate Dominance

BNY is arming 20,000 employees with OpenAI. This isn't just about efficiency—it's a new blueprint for enterprise AI that will create a new class of winners and losers.

Chai Discovery's $1.3B Valuation Isn't About Drugs—It's About the AI Platform Wars Invading Biotech
TechEN
Chai Discovery's $1.3B Valuation Isn't About Drugs—It's About the AI Platform Wars Invading Biotech

Chai Discovery's $130M raise at a $1.3B valuation isn't about a single drug. It's a strategic move by OpenAI's ecosystem to build the dominant AI platform for biotech.

OpenAI's Silent GPT-5.2 Update Is The Loudest Signal Yet About AI's New Reality
TechEN
OpenAI's Silent GPT-5.2 Update Is The Loudest Signal Yet About AI's New Reality

OpenAI's quiet GPT-5.2 update is a strategic signal. Our analysis reveals why this shift from hype to stability marks a new, more mature era for the AI industry.

OpenAI's GPT-5.2 Just Turned AI into a Scientist. This Changes Everything.
TechEN
OpenAI's GPT-5.2 Just Turned AI into a Scientist. This Changes Everything.

OpenAI's GPT-5.2 isn't just another upgrade. Its mastery of math and science signals a fundamental shift from creative AI to a new era of automated discovery.

Beyond the 'Blip': Why OpenAI's Comms Chief Exit Signals a New Corporate Era
TechEN
Beyond the 'Blip': Why OpenAI's Comms Chief Exit Signals a New Corporate Era

OpenAI's comms chief Hannah Wong is leaving. Her exit signals a major strategic shift from crisis management to corporate maturity. Here's what it means for the AI industry.

BNY's Radical AI Gambit: Why Arming 20,000 Employees with AI is More Than Just a Tech Upgrade
TechEN
BNY's Radical AI Gambit: Why Arming 20,000 Employees with AI is More Than Just a Tech Upgrade

BNY is enabling 20,000 employees to build AI agents with OpenAI. Our analysis reveals why this is a radical shift in enterprise AI strategy, not just another tech rollout.

BBVA's OpenAI Gambit: Why Its 120,000-Employee AI Rollout Is a Warning Shot to Global Finance
TechEN
BBVA's OpenAI Gambit: Why Its 120,000-Employee AI Rollout Is a Warning Shot to Global Finance

BBVA's deal to give 120,000 employees ChatGPT isn't a pilot—it's a radical bet on an AI-native future. Our analysis on why it changes everything for banking.

OpenAI's GPT-5.2: The 'Math-Brain' AI That Will Reshape Science and Industry
TechEN
OpenAI's GPT-5.2: The 'Math-Brain' AI That Will Reshape Science and Industry

Beyond chatbots: OpenAI's GPT-5.2 excels at math and science, signaling a shift from creative AI to verifiable, industrial-grade reasoning. What this means for R&D and investment.

Disney's OpenAI Deal Isn't a Partnership – It's a One-Year Audition for All of AI
TechEN
Disney's OpenAI Deal Isn't a Partnership – It's a One-Year Audition for All of AI

Disney's OpenAI deal isn't a simple partnership. Discover the strategic genius behind its one-year exclusivity clause and how it sets the stage for a massive AI bidding war.

The OpenAI Mafia Invades Pharma: Why Chai Discovery's $1.3B Bet is Reshaping Drug Discovery
TechEN
The OpenAI Mafia Invades Pharma: Why Chai Discovery's $1.3B Bet is Reshaping Drug Discovery

Chai Discovery's $130M raise at a $1.3B valuation isn't a funding story. It's a signal that elite AI talent is targeting pharma's core business model.